Cargando…
The War on Cancer An Anatomy of Failure, A Blueprint for the Future /
After reviewing the history of cancer and its impact on the population, Dr. Faguet exposes the antiquated notions that have driven cancer drug development, documents the stagnation in treatment outcomes despite major advances in cancer genomics and growing NCI budgets, and identifies the multiple fa...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Autor Corporativo: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Dordrecht :
Springer Netherlands : Imprint: Springer,
2005.
|
| Edición: | 1st ed. 2005. |
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-1-4020-3617-0 | ||
| 003 | DE-He213 | ||
| 005 | 20220120170236.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 100301s2005 ne | s |||| 0|eng d | ||
| 020 | |a 9781402036170 |9 978-1-4020-3617-0 | ||
| 024 | 7 | |a 10.1007/978-1-4020-3617-0 |2 doi | |
| 050 | 4 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 571.978 |2 23 |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 100 | 1 | |a Faguet, Guy B. |e author. |4 aut |4 http://id.loc.gov/vocabulary/relators/aut | |
| 245 | 1 | 4 | |a The War on Cancer |h [electronic resource] : |b An Anatomy of Failure, A Blueprint for the Future / |c by Guy B. Faguet. |
| 250 | |a 1st ed. 2005. | ||
| 264 | 1 | |a Dordrecht : |b Springer Netherlands : |b Imprint: Springer, |c 2005. | |
| 300 | |a XV, 227 p. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a Cancer Statistics: Some Facts -- Assessing the magnitude of the problem -- The problem is growing, not going away -- What Is Cancer? -- Cancer through the ages -- Our current understanding -- How Is Cancer Treated? -- The cancer cell-kill paradigm and its corollaries -- Chemotherapy drugs -- Treatment outcomes: Dismal by any standard -- Why Does This System Persist? -- The role of the National Cancer Institute -- Publications: The facts and nothing but the facts? -- From the doctors' perspective -- From the patients' perspective -- Where Do We Go From Here? -- A vision for the future -- Shifting from the cell-kill paradigm to pharmacogenomics. | |
| 520 | |a After reviewing the history of cancer and its impact on the population, Dr. Faguet exposes the antiquated notions that have driven cancer drug development, documents the stagnation in treatment outcomes despite major advances in cancer genomics and growing NCI budgets, and identifies the multiple factors that sustain the status quo. He shows that, contrary to frequent announcements of breakthroughs, our current cancer control model cannot eradicate most cancers and the reasons why. Significantly, this book also delineates a way forward via a shift from the discredited cell-kill approach of the past to an integrated, evidence-driven cancer control paradigm based on prevention, early diagnosis, and pharmacogenomics. The author's views are based on data published in mainstream scientific journals and other reliable references, 432 of which are cited. | ||
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Oncology. | |
| 650 | 0 | |a Medicine-Research. | |
| 650 | 0 | |a Biology-Research. | |
| 650 | 0 | |a Medical sciences. | |
| 650 | 0 | |a Medical genetics. | |
| 650 | 1 | 4 | |a Cancer Biology. |
| 650 | 2 | 4 | |a Oncology. |
| 650 | 2 | 4 | |a Biomedical Research. |
| 650 | 2 | 4 | |a Health Sciences. |
| 650 | 2 | 4 | |a Medical Genetics. |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9789048103942 |
| 776 | 0 | 8 | |i Printed edition: |z 9781402036187 |
| 776 | 0 | 8 | |i Printed edition: |z 9781402086205 |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-1-4020-3617-0 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||